We use cookies to improve your experience and for marketing. Read our cookie policy or manage cookies.

Accept essential cookies
Accept all cookies
Sign in
Sign in
Companies → Shenzhen Neptunus Bioengineering Co., Ltd.
Save to list
Remove

Shenzhen Neptunus Bioengineering Co., Ltd.

China, Guangdong, Shenzhen
Report a bug?
Claim ownership and edit
Description
Shenzhen Neptunus Bioengineering Co., Ltd. engages in the research and development, production, and sales of Chinese patent medicines, infusion products, and western medicine preparations in China. The company provides oryzanol tablets, chlorpheniramine tablets, chlorpheniramine maleate tablets, and rifampicin capsules, as well as technical support for generic drug quality consistency evaluation and other medical research and development work. It also distributes drugs, medical devices, and other medical supplies; and provides value-added services for hospitals, medical institutions, and drug retail institutions and distributors. The company offers drugs in the fields of malignant tumors, cardiovascular and cerebrovascular diseases, neurodegenerative diseases, diabetes, infectious diseases, and multiple diseases, such as respiratory system and digestive system. Shenzhen Neptunus Bioengineering Co., Ltd. was founded in 1989 and is headquartered in Shenzhen, China.
Industries
SIC
Address:

Floor 24

Haiwang Yinhe Technology Building

No.1

KejiM. 3rd Road

Nanshan District Shenzhen

Guangdong

518057 China

Website:
Revenue
Recent news:

Westin Desaru Coast Resort partners with CAYIN Technology for digital signage

The partnership involves the implementation of the CMS-WS server and CAYIN Signage Player.

Source: Hotel Management Network Sep 9, 2025

Nifty clocks fifth session of gains led by IT on Infosys buyback, US rate cut hopes

India's benchmark Nifty 50 closed higher for a fifth consecutive session on Tuesday, with gains led by information technology stocks on Infosys' share buyback plan and U.S. interest rate cut prospects. The Nifty 50 and the BSE Sensex gained 0.39% each to 24,868.6 and 81,101.32 points, respectively. IT jumped 2.8%, led by a 5% surge in Infosys after it announced plans to consider a share buyback on September 11.

Source: Reuters Sep 9, 2025

SZSE - Delayed Quote - CNY
000078.SZ
Candle
Line
1M
6M
1Y
5Y
Financial Statistics
Valuation Measures
Current
Quarterly
As of 03/22/2026
Market Cap: 8.02 B
Enterprise Value: 16.36 B
Trailing P/E: N/A
Forward P/E: 9.31
PEG Ratio (5yr expected): N/A
Price/Sales (ttm): 0.29
Price/Book (mrq): 4.40
Enterprise Value/Revenue: 0.60
Enterprise Value/EBITDA: 579.45
Financial Highlights
Profitability and Income Statement
Profit Margin: -4.45%
Return on Assets (ttm): -0.25%
Return on Equity (ttm): -34.82%
Revenue (ttm): 27.28 B
Net Income Avi to Common (ttm): -1.21 B
Diluted EPS (ttm): -0.46
Balance Sheet and Cash Flow
Total Cash (mrq): 2.20 B
Total Debt/Equity (mrq): 370.32%
Levered Free Cash Flow (ttm): -406.62 M
Company is likely to buy
Company is likely to sell
Disclaimer:

IndexBox is not affiliated with, associated with, or endorsed by this company in any way. The information provided on this page, including company details, is solely for informational purposes. IndexBox makes no representations or warranties about the accuracy or completeness of the information provided.

All data and information is provided “as is” for informational purposes only, and is not intended for trading purposes or financial, investment, tax, legal, accounting or other advice. Please consult your broker or financial representative to verify pricing before executing any trade. IndexBox is not an investment adviser, financial adviser or a securities broker. None of the data and information constitutes investment advice nor an offering, recommendation or solicitation by IndexBox to buy, sell or hold any security or financial product, and IndexBox makes no representation (and has no opinion) regarding the advisability or suitability of any investment.